| Orginal Article |
|
|
|
|
| Current Status and Trend of R&D of Microecological Drugs |
GAO Qian1,**( ),ZHANG Hong-xiang2,3,JIANG Hong1,YE Mao1 |
| 3 Chinese Society of Biotechnology,Beijing 100101, China |
|
|
|
Abstract In the recent years, numerous studies highlighted the potential role of microecological drugs in treating multiple diseases and preserving host’s health. In this paper, all the data was extracted from Clarivate via Cortellis. The results of qualitative analysis and expert wisdom were as follows. Up to data, 142 kinds of microecological drugs have been identified and 49 kinds of them have been undergone clinical trials. The United States was far ahead of other countries with 70 percent of the amount in microecological drugs. The drug indications were focused on Clostridium difficile infection, inflammatory bowel disease and ulcerative colitis. The key players have established advanced experimental platforms for discovery and development of novel product candidates, while 4D pharma was a world leader in this field. There were seven drugs in phase 3 clinical development. Access to 303 microecological drugs deal records, the maximum transaction was $2.78 billion. In the future, microecological drugs may make a major breakthrough in cancer and nervous system diseases treatment.
|
|
Received: 16 September 2019
Published: 27 March 2020
|
|
|
|
Corresponding Authors:
Qian GAO
E-mail: gaoq@mail.whlib.ac.cn
|
|
|
| [1] |
施慧琳, 王玥, 苏燕 , 等. 人类微生物组产业发展态势及建议. 中国生物工程杂志, 2019,39(6):97-103.
|
|
|
| [1] |
Shi H L, Wang Y, Su Y , et al. The development trend and suggestions of human microbiome industry. China Biotechnology, 2019,39(6):97-103.
|
|
|
| [2] |
4D pharma acquires Tucana Health. [2016-2-10]. http://www.stockmarketwire.com/article/5210430/4D-ph-arma-acquires-Tucana-Health.html.
|
|
|
| [3] |
Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc. [2018-4-5]. https://www.rebiotix.com/news-media/press-releases/ferring-acquires-innovative-biotechnology-company-and-microbiome-pioneer-rebiotix-inc/.
|
|
|
| [4] |
Lagier J C, Cadoret F, Raoult D . Critical microbiological view of SER-109. The Journal of Infectious Diseases, 2017,215(1):161-162.
|
|
|
| [5] |
Collins J, Auchtung J M . Control of Clostridium difficile infection by defined microbial communities // Robert A B, Patrice D C. Bugs as Drugs: Therapeutic Microbes for the Prevention and Treatment of Disease.Washington:ASM. 2018.
|
|
|
| [6] |
OxThera initiates extension part of a phase 3 study of oxabact in primary hyperoxaluria. [2019-6-20]. https://www.prnewswire.com/news-releases/oxthera-initiates-extension-part-of-a-phase-3-study-of-oxabact-in-primary-hyperoxaluria-300871682.html.
|
|
|
| [7] |
Blount K F, Shannon W D, Deych E , et al. Restoration of bacterial microbiome composition and diversity among treatment responders in a phase 2 trial of RBX2660: An investigational microbiome restoration therapeutic. Open Forum Infectious Diseases, 2019, 6(4): ofz095.
|
|
|
| [8] |
Mische S, Orenstein R, Dubberke E R . et al. 1950. Prevention of recurrent clostridium difficile at six months following treatment with microbiota-based therapy RBX2660: durability results from a phase 2 open-label study. Open Forum Infectious Diseases, 2018,5(Suppl 1):S562-S563.
|
|
|
| [9] |
Allergan enters into licensing agreement with assembly biosciences to obtain worldwide rights to microbiome gastrointestinal development programs. [2017-1-9]. https://www.prnewswire.com/news-releases/allergan-enters-into-licensing-agreement-with-assembly-biosciences-to-obtain-worldwide-rights-to-microbiome-gastrointestinal-development-programs-300387518.html.
|
|
|
| [10] |
Nestle Health Science makes latest move in breakthrough microbiome field. [2016-1-11]. https://www.nestlehealthscience.com/newsroom/press-releases/strategic-collaboration.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
